Skip to main content

Table 4 Comparison of average IOP reductions between the phaco/ECP, phaco/MP-TSCPC, and phaco alone groups

From: Transscleral vs endoscopic cyclophotocoagulation: safety and efficacy when combined with phacoemulsification

Mean IOP reduction (mm Hg ± SD)

p-value

 

phaco

phaco/MP-TSCPC

phaco/ECP

phaco vs phaco/ECP

phaco vs phaco/MP-TSCPC

phaco/ECP vs phaco/MP-TSCPC

Day 1 (% reduction)

-5.13 ± 9.2 (35.9)

0.53 ± 4.5 (2.9)

-3.13 ± 4.3 (-19.9)

0.69

0.16

0.39

n

19

20

25

   

Week 1(% reduction)

0.04 ± 2.23 (0.3)

2.13 ± 7.3 (11.6)

4.68 ± 5.6 (29.7)

0.18

0.13

0.41

n

17

20

24

   

Week 6 (% reduction)

0.72 ± 2.25(5.0)

6.03 ± 6.8 (32.8)

2.83 ± 9.3(17.9)

0.33

 < 0.01*

0.02*

n

19

18

19

   

Month 3 (% reduction)

0.53 ± 1.65 (3.7)

8.53 ± 6.8 (46.4)

2.81 ± 4.0 (17.8)

0.24

 < 0.01*

 < 0.01*

n

16

18

21

   

Month 6 (% reduction)

1.86 ± 1.2 (1.3)

6.80 ± 4.4 (37.0)

2.70 ± 5.0 (17.1)

0.38

0.02*

0.08

n

18

18

25

   

Year 1 (% reduction)

1.0 ± 1.6 (7.0)

6.0 ± 4.3 (32.7)

3.07 ± 5.3 (19.5)

0.24

0.10

0.10

n

17

19

23

   
  1. A negative IOP reduction indicates an increase in IOP postoperatively, n = number of patients at each follow-up visit
  2. IOP Intraocular pressure, mm Hg millimeters of Mercury, phaco phacoemulsification, MP-TSCPC Micropulse Transscleral Cyclophotocoagulation (IRIDEX Corp., Mountainview, CA), ECP Endoscopic cyclophotocoagulation, (SD) Standard deviation
  3. * Indicates a significant difference